Population Pharmacokinetic (Pk)/Pharmacodynamic (Pd) Modeling Of Myelosuppression In Patients With Hematologic Malignancies For Cpx-351 And Standard-Of-Care 7+3 Therapy

CPX-351 (Vyxeos®), a liposomal encapsulation of cytarabine and daunorubicin at a synergistic ratio, has demonstrated a significant survival benefit vs standard 7+3 in patients (pts) with high-risk/secondary AML. A population PK/PD analysis assessed the correlation between cytarabine and daunorubicin plasma concentrations and myelosuppressive effects (neutropenia, thrombocytopenia) of CPX-351 and 7+3.